Information on EC 1.14.99.1 - prostaglandin-endoperoxide synthase

New: Word Map on EC 1.14.99.1
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota

EC NUMBER
COMMENTARY hide
1.14.99.1
-
RECOMMENDED NAME
GeneOntology No.
prostaglandin-endoperoxide synthase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
arachidonate + AH2 + 2 O2 = prostaglandin H2 + A + H2O
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
oxidation
redox reaction
-
-
-
-
reduction
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
arachidonic acid metabolism
-
-
Arachidonic acid metabolism
-
-
C20 prostanoid biosynthesis
-
-
Metabolic pathways
-
-
SYSTEMATIC NAME
IUBMB Comments
(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor:oxygen oxidoreductase
This enzyme acts both as a dioxygenase and as a peroxidase.
CAS REGISTRY NUMBER
COMMENTARY hide
39391-18-9
-
9055-65-6
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
collected on the coast of the Baltic Sea in Kassari Bay
UniProt
Manually annotated by BRENDA team
collected from the coast of Kanagawa Prefecture in Tokyo Bay
UniProt
Manually annotated by BRENDA team
squirrel monkey
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
evolution
the algal PGHS lacks structural elements identified in all known animal PGHSs, such as epidermal growth factor-like domain and helix B in the membrane binding domain. The key residues of animal PGHS, like catalytic Tyr385 and heme liganding His388 are conserved in the algal enzyme, but the amino acid residues shown to be important for substrate binding and coordination, and the target residues for nonsteroidal anti-inflammatory drugs, Arg120, Tyr355, and Ser530, are not found at the appropriate positions in the algal sequences. The preferred substrate for the algal PGHS is arachidonic acid with cyclooxygenase reaction rate remarkably higher than values reported for mammalian PGHS isoforms
malfunction
PGHS-1 inhibition in activated human plateletts significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
metabolism
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid + AH2 + O2
? + A + H2O
show the reaction diagram
(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoic acid + AH2 + O2
? + A + H2O
show the reaction diagram
substrate binding structure and nonproductive conformation, overview
-
-
?
8,11,14-eicosatrienoic acid + O2
prostaglandin G1 + ?
show the reaction diagram
8,11,14-eicosatrienoic acid + O2
prostaglandin H1 + ?
show the reaction diagram
arachidonate + 2 O2
prostaglandin G2
show the reaction diagram
-
-
-
-
?
arachidonate + AH2 + 2 O2
prostaglandin G2 + A + H2O
show the reaction diagram
arachidonate + AH2 + 2 O2
prostaglandin H2 + A + H2O
show the reaction diagram
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
show the reaction diagram
arachidonate + electron donor + O2
prostaglandin H2 + oxidized electron donor + H2O
show the reaction diagram
arachidonate + reduced N,N,N',N'-tetramethylphenylenediamine + 2 O2
prostaglandin G2 + oxidized N,N,N',N'-tetramethylphenylenediamine + H2O
show the reaction diagram
-
-
-
?
arachidonate + reduced N,N,N',N'-tetramethylphenylenediamine + 2 O2
prostaglandin H2 + oxidized N,N,N',N'-tetramethylphenylenediamine + H2O
show the reaction diagram
arachidonic acid + 2 O2
prostaglandin G2
show the reaction diagram
cyclooxygenase reaction, arachidonic acid as electron donor
-
-
?
arachidonic acid + 3,4-methylenedioxyamphetamine
?
show the reaction diagram
-
postulated bioactivation to a neurodegenerative free radical intermediate that can initiate the formation of reactive oxygen species
-
-
?
arachidonic acid + 3,4-methylenedioxymethamphetamine
?
show the reaction diagram
-
postulated bioactivation to a neurodegenerative free radical intermediate that can initiate the formation of reactive oxygen species
-
-
?
arachidonic acid + AH2 + 2 O2
15(R)-hydroxy-eicosatetraenoic acid + A + ?
show the reaction diagram
arachidonic acid + AH2 + 2 O2
15-hydroperoxy-9alpha,11alpha-peroxiprosta-5,13-dienoic acid + A + ?
show the reaction diagram
-
-
-
?
arachidonic acid + AH2 + 2 O2
6-keto-prostaglandin F1alpha + A + ?
show the reaction diagram
-
activity assay
-
-
?
arachidonic acid + AH2 + 2 O2
prostaglandin E2 + A + ?
show the reaction diagram
-
-
-
?
arachidonic acid + AH2 + O2
prostaglandin E2 + ?
show the reaction diagram
arachidonic acid + methamphetamine
?
show the reaction diagram
-
postulated bioactivation to a neurodegenerative free radical intermediate that can initiate the formation of reactive oxygen species
-
-
?
cis-11,14-eicosadienoic acid + AH2 + O2
?
show the reaction diagram
-
-
-
?
cis-4,7,10,13,16,19-docosahexaenoic acid + AH2 + O2
?
show the reaction diagram
-
-
-
?
cis-5,8,11,14,17-eicosapentaenoic acid + AH2 + O2
?
show the reaction diagram
-
-
-
?
cis-5,8,11,14-eicosatetraenoic acid + AH2 + O2
?
show the reaction diagram
-
-
-
?
cis-7,10,13,16-docosatetraenoic acid + AH2 + O2
?
show the reaction diagram
-
-
-
?
cis-8,11,14-eicosatrienoic acid + AH2 + O2
?
show the reaction diagram
-
-
-
?
gamma-linolenic acid + AH2 + O2
?
show the reaction diagram
-
-
-
?
guaiacol + trans-5-phenyl-4-pentenyl-1-hydroperoxide
?
show the reaction diagram
-
-
-
-
?
H2O2 + guaiacol
?
show the reaction diagram
-
peroxidase activity
-
-
?
H2O2 + N,N,N',N'-tetramethyl-p-phenylenediamine
?
show the reaction diagram
-
peroxidase activity
-
-
?
linoleic acid + AH2 + O2
9-hydroxyoctadecadienoic acid + 13-hydroxyoctadecadienoic acid + ?
show the reaction diagram
linolenic acid + AH2 + O2
?
show the reaction diagram
-
-
-
?
prostaglandin G2 + AH2
prostaglandin H2 + A + H2O
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
arachidonate + 2 O2
prostaglandin G2
show the reaction diagram
-
-
-
-
?
arachidonate + AH2 + 2 O2
prostaglandin G2 + A + H2O
show the reaction diagram
arachidonate + AH2 + 2 O2
prostaglandin H2 + A + H2O
show the reaction diagram
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
show the reaction diagram
prostaglandin G2 + AH2
prostaglandin H2 + A + H2O
show the reaction diagram
-
-
-
-
?
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
Hematin
-
;
iron-protoporphyrin IX
each subunit contains a molecule of Fe3+-protoporphyrin IX noncovalently attached to the enzyme, the heme group is essential for both enzyme activities; each subunit contains a molecule of Fe3+-protoporphyrin IX noncovalently attached to the enzyme, the heme group is essential for both enzyme activities
additional information
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Fe2+
ferric heme enzyme
Mn3+
-
substitution of ferric heme by MnIII protoporphyrin IX greatly diminishes the peroxidase activity, but has little effect on the cyclooxygenase activity
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1,10-phenanthroline
-
weak
1-Mercapto-9,11,15-trihydroxyprosta-5,13-diene
-
inhibition of prostaglandin G1 synthesis
1-Mercapto-9-oxo-11,15-dihydroxyprosta-5,13-dione
-
inhibition of prostaglandin G1 synthesis
12-nitroarachidonic acid
nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase and peroxidase activity PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
14-nitroarachidonic acid
nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase and peroxidase activity PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
15-nitroarachidonic acid
nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase and peroxidase activity PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
2,2'-bipyridyl
-
weak
2,3-Dimercaptopropanol
-
inhibition of prostaglandin G1 synthesis
2-hydroxybutyric acid
-
weak
5,8,11,14-Eicosatetraynoic acid
5-bromo-2-[4-fluorophenyl]-3-[4-methylsulfonylphenyl]-thiophene
6-methoxy-2-naphthyl acetic acid
-
active metabolite of nabumetone, isozyme 1, 50% inhibition at 0.2-0.8 mM, isozyme 2, 50% inhibition at 0.015-0.55 mM
6-methylnaphthylacetic acid
-
recombinant protein, 50% inhibition at 0.08-0.1 mM
6-[2,4-difluorophenoxy]-5-methyl-sulfonylamino-1-indanone
-
CGP28238, an isozyme-2 specific inhibitor, 65% inhibition at 100 nM
8-hydroxyquinoline
-
-
9,11-Dihydroxy-15S-mercaptoprosta-5,13-dienoic acid
-
or 15R-isomer, inhibition of prostaglandin G1 synthesis
9-nitroarachidonic acid
nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase activity and peroxidase activity of PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
acetoacetic acid
-
weak
Acetylsalicylic acid
albumin
alpha-linolenic acid
-
;
anilorac
-
isozyme 1, 50% inhibition at 0.0007 mM, isozyme 2, 50% inhibition at 0.009 mM
-
aspirin
bicarbonate
-
bicarbonate enhances peroxynitrite-mediated peroxidase inactivation
Butyric acid
-
-
BW 755C
-
recombinant protein, 50% inhibition at 0.01-0.02 mM
celecoxib
-
;
crotonic acid
-
-
DCM-extract of Angelicae dahuricae radix
-
0.1% inhibition of PGHS-1; 38.8% inhibition of PGHS-2
-
DCM-extract of Angelicae sinsesis radix
-
55.8% inhibition of PGHS-2; 75.0% inhibition of PGHS-1
-
DCM-extract of Atractylodis lanceae rhizoma
-
46.9% inhibition of PGHS-1; 50.3% inhibition of PGHS-2
-
DCM-extract of Atractylodis macrocephalae rhizoma
-
47.0% inhibition of PGHS-2; 58.6% inhibition of PGHS-1
-
DCM-extract of Cinnamomi ramulus
-
48.4% inhibition of PGHS-2; 73.5% inhibition of PGHS-1
-
DCM-extract of Houttuyniae herba
-
40.9% inhibition of PGHS-2; 46.8% inhibition of PGHS-1
-
DCM-extract of Notopterygii rhizoma seu radix
-
-2.1% inhibition of PGHS-2; 42.6% inhibition of PGHS-1
-
DCM-extract of Piperis sarmentosi herba
-
10.1% inhibition of PGHS-2; 47.2% inhibition of PGHS-1
-
DCM-extract of Platycodi radix
-
70.1% inhibition of PGHS-2; 77.8% inhibition of PGHS-1
-
DCM-extract of Zanthoxyli pericarpium
-
18.3% inhibition of PGHS-1; 31.3% inhibition of PGHS-2
-
DCM-extract of Zingiberis rhizoma
-
41.3% inhibition of PGHS-2; 52.9% inhibition of PGHS-1
-
diclofenac
diethyldithiocarbamate
-
-
Dihydrolipoic acid
-
inhibition of prostaglandin G1 synthesis
dithiothreitol
-
inhibition of prostaglandin G1 synthesis
DL-Propanolol
-
-
docosahexaenoic acid
-
isozyme 1, 50% inhibition at 0.011 mM, isozyme 2, 50% inhibition at 0.015 mM
DUP-697
Eicosa-5,8,11,14-tetraynoic acid
-
-
ellagic acid
-
at high concentration and in presence of cofactors inhibition, at low concentrations stimulation
etodalac
-
recombinant protein, 50% inhibition at 0.06-0.07 mM
ETYA
-
recombinant protein, 50% inhibition at 0.015-0.025 mM
fatty acid
-
of low molecular mass
fenclofenac
-
isozyme 1, 50% inhibition at 0.007 mM, isozyme 2, 50% inhibition at 0.004 mM
flosulide
-
selective for isozyme 2, 50% inhibition at 130 nM
Flufenamic acid
-
50% inhibition at 0.02 mM
flurbiprofen
Haptoglobin
-
-
-
Human serum
-
-
-
Ibuprofen
indomethacin
Ketoprofen
L-745
-
isozyme 1, 50% inhibition at 0.369 mM, isozyme 2, 50% inhibition at 0.002 mM
-
linoleic acid
-
;
Meclofenamic acid
Mefenamic acid
-
isozyme 1, 50% inhibition at 0.01 mM, isozyme 2, 50% inhibition at 0.0003 mM
meloxicam
-
isozyme 1, 50% inhibition at 0.005 mM, isozyme 2, 50% inhibition at 0.0004 mM
n-hexane extract of Angelicae dahuricae radix
-
42.4% inhibition of PGHS-2; 52.5% inhibition of PGHS-1
-
n-hexane extract of Angelicae sinsesis radix
-
61.5% inhibition of PGHS-2; 73.0% inhibition of PGHS-1
-
n-hexane extract of Atractylodis lanceae rhizoma
-
67.4% inhibition of PGHS-1; 68.3% inhibition of PGHS-2
-
n-hexane extract of Atractylodis macrocephalae rhizoma
-
46.1% inhibition of PGHS-1; 48.9% inhibition of PGHS-2
-
n-hexane extract of Cinnamomi ramulus
-
23.6% inhibition of PGHS-2; 46.6% inhibition of PGHS-1
-
n-hexane extract of Houttuyniae herba
-
43.4% inhibition of PGHS-2; 50.3% inhibition of PGHS-1
-
n-hexane extract of Notopterygii rhizoma seu radix
-
64.9% inhibition of PGHS-2; 69.6% inhibition of PGHS-1
-
n-hexane extract of Piperis sarmentosi herba
-
52.4% inhibition of PGHS-1; 65.0% inhibition of PGHS-2
-
n-hexane extract of Platycodi radix
-
48.7% inhibition of PGHS-1; 55.1% inhibition of PGHS-2
-
n-hexane extract of Zanthoxyli pericarpium
-
24.9% inhibition of PGHS-2; 48.5% inhibition of PGHS-1
-
n-hexane extract of Zingiberis rhizoma
-
77.5% inhibition of PGHS-2; 83.4% inhibition of PGHS-1
-
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
naproxen
niflumic acid
-
isozyme 1, 50% inhibition at 0.016 mM, isozyme 2, 50% inhibition at 0.0001 mM
nimesulide
Non-steroidal anti-inflammatory agents
NS-398
O2
-
the cyclooxygenase reaction is inhibited by an excess of dissolved oxygen, 0.5 mM O2 causes twofold decrease in the initial rate and maximal yield
oleic acid
-
;
p-Aminophenol
-
-
PD-98059
-
MEK inhibitor, blocks specifically the activation of ERK1/2 and the PGHS-2 mRNA response to oxygen and glucose depivation, hence ERK is a mediator of PGHS-2 gene expression
peroxynitrite
-
-
piroxicam
Propionic acid
-
-
quercetin
quercetin 3-O-glucoside
SB203580
-
inhibitor of p38, reduces the PGHS-2 response to oxygen and glucose depivation by approximately 50%
SC-560
SC58125
-
isozyme 1, 50% inhibition at 0.039 mM, isozyme 2, 50% inhibition at 0.0003 mM
sulindac sulfide
-
isozyme 1, 50% inhibition at 0.0004 mM, isozyme 2, 50% inhibition at 0.012 mM
suprofen
-
isozyme 1, 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.002mM
Tannic acid
-
at high concentration and in presence of cofactors inhibition, at low concentrations stimulation
U0126
-
MEK inhibitor, blocks specifically the activation of ERK1/2 and the PGHS-2 mRNA response to oxygen and glucose depivation, hence ERK is a mediator of PGHS-2 gene expression
valeryl salicylate
-
-
additional information
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
5-hydroxytryptamine
-
stimulates
arachidonate
-
-
arachidonic acid
-
exogenous, increases hPHS activity
benzoquinone
-
stimulates conversion of prostaglandin G1 to H1
cysteine
-
stimulates
dopamine
ellagic acid
-
at high concentration and in presence of cofactors inhibition, at low concentrations stimulation
epinephrine
glutathione
-
promotes prostaglandin H synthase-dependent formation of oxidative stress biomarkers malondialdehyde and 15(S)-8-iso-prostaglandin F2alpha; promotes prostaglandin H synthase-dependent formation of oxidative stress biomarkers malondialdehyde and 15(S)-8-iso-prostaglandin F2alpha
Hemin
-
activates
hydroperoxyeicosatetraenoic acid
-
-
-
hydroquinone
indole
-
stimulates conversion of prostaglandin G1 to H1
kynurenine
-
stimulates conversion of prostaglandin G1 to H1
Melatonin
norepinephrine
-
-
Oestrogens
-
weak stimulation
-
peroxynitrite
-
peroxidase activity, MS-analysis reveals that tyrosine 385 is a target for nitration by ONOO- only when heme is present
phenylalanine
-
stimulates conversion of prostaglandin G1 to H1
quinol
-
stimulates
reduced glutathione
-
stimulates
serotonin
Tannic acid
-
at high concentration and in presence of cofactors inhibition, at low concentrations stimulation
Thyroid hormones
-
weak stimulation
-
thyrotropin
-
tissue-specific stimulation in thyroid
-
tryptophan
-
stimulates conversion of prostaglandin G1 to H1
tyrosine
-
stimulates conversion of prostaglandin G1 to H1
additional information
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0368
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid
pH 8.0, 25C, COX-2 mutant N580A
0.00945
(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoic acid
pH 8.0, 25C, COX-2 mutant N580A
0.0031 - 0.082
alpha-linolenic acid
0.0009 - 0.015
arachidonate
0.001 - 0.16
arachidonic acid
0.0052 - 0.0091
cis-11,14-eicosadienoic acid
0.0011 - 0.07
cis-4,7,10,13,16,19-docosahexaenoic acid
0.0012 - 0.039
cis-5,8,11,14,17-eicosapentaenoic acid
0.0017 - 0.013
cis-5,8,11,14-eicosatetraenoic acid
0.0027 - 0.061
cis-7,10,13,16-docosatetraenoic acid
0.002 - 0.036
cis-8,11,14-eicosatrienoic acid
0.0048 - 0.162
gamma-linolenic acid
0.08 - 0.29
guaiacol
1.3 - 5.5
H2O2
0.0055 - 0.0068
linoleic acid
0.0083 - 0.0854
N,N,N',N'-tetramethyl-p-phenylenediamine
0.005 - 0.011
O2
0.02 - 0.437
trans-5-phenyl-4-pentenyl-1-hydroperoxide
additional information
additional information
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
3.45
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid
Mus musculus
Q05769
pH 8.0, 25C, COX-2 mutant N580A
8.7
(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoic acid
Mus musculus
Q05769
pH 8.0, 25C, COX-2 mutant N580A
27
arachidonate
Mus musculus
Q05769
pH 8.0, 25C, COX-2 mutant N580A
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
9
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid
Mus musculus
Q05769
pH 8.0, 25C, COX-2 mutant N580A
40206
920
(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoic acid
Mus musculus
Q05769
pH 8.0, 25C, COX-2 mutant N580A
41642
5240
arachidonate
Mus musculus
Q05769
pH 8.0, 25C, COX-2 mutant N580A
619
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.005
indomethacin
-
-
0.00027 - 0.001
nimesulide
additional information
additional information
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.003 - 0.0212
alpha-linolenic acid
0.0008 - 0.0009
indomethacin
0.0026 - 0.0198
linoleic acid
0.0507
NS-398
Ovis aries
-
inhibition of PGHS-1
0.1226 - 0.1245
oleic acid
0.0186 - 0.0388
peroxynitrite
0.018 - 0.086
quercetin
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.0027
-
mutant Y348F, cyclooxygenase activity
0.0039
-
mutant Y504F, cyclooxygenase activity
0.0047
-
mutant Y348F/Y504F, cyclooxygenase activity
0.0058
-
wild-type, cyclooxygenase activity
2.4
-
prostaglandin H1 synthesis
2300
cyclooxygenase activity for partially purified prostaglandin H synthase 1 of Salvelinus fontinalis, tPGHS-1
4220
-
purified recombinant His6-tagged PGHS-2, pH 8.0, 37C
15000
cyclooxygenase activity for partially purified prostaglandin H synthase 2 of Salvelinus fontinalis, tPGHS-2
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7 - 7.3
-
formation of prostaglandin E2 from arachidonic acid
7.5 - 8
-
formation of prostaglandin F2alpha
7.8
-
enzyme-linked immunoassay for PGE2
8 - 8.5
-
formation of prostaglandin E2 and D2
8.1
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
6.5 - 9
-
about 70% of maximum activity at pH 6.0 and 9.0 of prostaglandin E2 formation, about 50% of maximum activity at pH 6.0 and 9.0 of prostaglandin F2alpha formation
7.2 - 9
-
about 60% of maximum activity at pH 7.2 and 9.0 of prostaglandin D2 formation
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5 - 30
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
seminal plasma induces and potentiates the expression of PTGS2 in cervicovaginal cells and tissues
Manually annotated by BRENDA team
endometrial stromal cells
Manually annotated by BRENDA team
-
caput and cauda
Manually annotated by BRENDA team
fetal; fetal
Manually annotated by BRENDA team
PTGS2, during early, mid, and late stages
Manually annotated by BRENDA team
-
isozyme 2
Manually annotated by BRENDA team
-
increased expression of PTGS2
Manually annotated by BRENDA team
-
human neuroblastoma cell
Manually annotated by BRENDA team
-
somatic and spermatogenic cells
Manually annotated by BRENDA team
-
vaginal cell line, expression of prostaglandin-endoperoxide synthase 2, i.e. cyclooxygenase 2, in human vaginal cells in response to toll-like receptor ligands and other proinflammatory stimuli, such vaginal mucosal irritant nonoxynol-9, in a synergistic manner
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
probably associated with
-
Manually annotated by BRENDA team
additional information
PDB
SCOP
CATH
ORGANISM
UNIPROT
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
65000
-
immunoblot
65620
-
amino acid sequence deduced from nucleotide sequence of cDNA, MW of unglycosylated enzyme
68000
-
human cyclooxygenase-1, estimated by SDS-PAGE and Western blotting, detected with a cyclooxygenase-1 antibody
70000
-
confirmed by SDS-PAGE, Western blot analysis and MALDI-TOF
73000
-
determined by SDS-PAGE and immunoblotting
300000 - 350000
-
gel filtration
330000
about, recombinant His-tagged enzyme, gel filtration
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
homodimer
tetramer
4 * 63500, recombinant His-tagged enzyme, SDS-PAGE
additional information
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
glycoprotein
Crystallization/COMMENTARY
ORGANISM
UNIPROT